Glycomimetics Inc (NASDAQ:GLYC) Institutional Investors Q1 2018 Sentiment

July 14, 2018 - By Michael Garrison

Sentiment for Glycomimetics Inc (NASDAQ:GLYC)

Glycomimetics Inc (NASDAQ:GLYC) institutional sentiment decreased to 1.63 in Q1 2018. Its down -0.87, from 2.5 in 2017Q4. The ratio dived, as 52 active investment managers increased or opened new holdings, while 32 cut down and sold stakes in Glycomimetics Inc. The active investment managers in our partner’s database now have: 42.95 million shares, up from 30.92 million shares in 2017Q4. Also, the number of active investment managers holding Glycomimetics Inc in their top 10 holdings decreased from 2 to 1 for a decrease of 1. Sold All: 17 Reduced: 15 Increased: 27 New Position: 25.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $727.46 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

The stock increased 1.78% or $0.3 during the last trading session, reaching $17.12. About 389,072 shares traded. GlycoMimetics, Inc. (NASDAQ:GLYC) has risen 27.86% since July 14, 2017 and is uptrending. It has outperformed by 15.29% the S&P500.

Analysts await GlycoMimetics, Inc. (NASDAQ:GLYC) to report earnings on August, 2. They expect $-0.33 earnings per share, down 10.00 % or $0.03 from last year’s $-0.3 per share. After $-0.33 actual earnings per share reported by GlycoMimetics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Nea Management Company Llc holds 6.2% of its portfolio in GlycoMimetics, Inc. for 8.58 million shares. Redmile Group Llc owns 2.28 million shares or 1.43% of their US portfolio. Moreover, Ghost Tree Capital Llc has 0.82% invested in the company for 250,000 shares. The Israel-based Sphera Funds Management Ltd. has invested 0.37% in the stock. Ra Capital Management Llc, a Massachusetts-based fund reported 253,547 shares.

Since January 1, 0001, it had 0 buys, and 6 sales for $1.20 million activity.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Ratings analysis reveals 100% of GlycoMimetics’s analysts are positive. Out of 2 Wall Street analysts rating GlycoMimetics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $25 while the high is $35.0. The stock’s average target of $30 is 75.23% above today’s ($17.12) share price. GLYC was included in 2 notes of analysts from February 8, 2018. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, March 7. The rating was maintained by Roth Capital on Thursday, February 8 with “Buy”.

GlycoMimetics, Inc. (NASDAQ:GLYC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.